Drug intelligence / Profile preview

PLSV-1

Development stage: Preclinical
Lead developer: Intralytix
Administration: Oral

Overview

PLSV-1 is a bacteriophage-based product developed by Intralytix, Inc. for veterinary applications. It is designed to prevent and treat bacterial diseases, specifically targeting Salmonella infections in poultry. The mechanism of action involves bacteriophages, which are viruses that infect and lyse specific bacterial cells, thereby disrupting bacterial metabolism and leading to their destruction. While not yet fully optimized for commercialization, preliminary proof-of-concept studies have demonstrated its safety and efficacy.

Brand names: PLSV-1PLSV1PLSV 1

Targets

Salmonella

Beyond the preview

Go deeper on PLSV-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PLSV-1.

Explore the full profile